Zhanfang Guo

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

X. Cynthia, Feng Gao, Jingqin Luo et al. · Clinical Cancer Research · 2017 · 376 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

X. Cynthia, Shirong Cai, Shunqiang Li et al. · Journal of Clinical Investigation · 2012 · 222 citations · Full text

Medicine, Cancer Biology, Oncology +17

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Kuan‐lin Huang, Shunqiang Li, Philipp Mertins et al. · Nature Communications · 2017 · 155 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

X. Cynthia, Matthew J. Ellis, Gina R. Petroni et al. · Breast Cancer Research and Treatment · 2012 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

X. Cynthia, Jingqin Luo, Michael Naughton et al. · Clinical Cancer Research · 2015 · 93 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17